Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of ProCervix plus imiquimod for HPV-16/18 clearance
NL-OMON41289Phase 2Active, not recruiting
- Sponsor
- Genticel
- Start
- Jul 2014
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in human papillomavirus infection, HPV16 infection (HPV16) and human papillomavirus infection type 18 comparing ProCervix + imiquimod with Placebo + imiquimod (2 arms). Primary endpoint: HPV 16/18 viral clearance at Month 12. Started Jul 2014; status: active, not recruiting.
02
Drugs
GTL001imiquimod
03
Conditions
human papillomavirus infectionHPV16 infection (HPV16)human papillomavirus infection type 18
Beyond the preview
Go deeper on NL-OMON41289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41289.